Archives 2009
- December 10, 2009
Azaya Therapeutics Receives FDA Authorization to Start Phase I Cancer Trial
More
October 5, 2009
Depomed, Inc. Announces Positive Top-Line Results from Phase 3
Clinical Trial of DM-1796 in Postherpetic Neuralgia
Menlo Park, Calif
More
September 22, 2009
Selexis and Neogenix Oncology enter into research services
agreement
Geneva, Switzerland, and Great Neck, New York
More
September 18, 2009
Wyeth and Ambrx Form Multi-target Alliance to Leverage Recent Ambrx
Biologics Platform Advances
Collegeville, PA and San Diego, CA
More
September 17, 2009
to-BBB technology will be used by MedImmune to evaluate brain
drug delivery mechanism
Leiden, The Netherlands
More
August 31, 2009
Selexis and NKT Therapeutics enter into research services
agreement
Geneva, Switzerland
More
August 10, 2009
Depomed Reports
Encouraging Results of its Phase I Trial for DM-1992 Program in Parkinson's
Disease
Menlo Park, Calif
More
August 6, 2009
to-BBB climbs up the international CNS drug delivery ranking
Leiden, The Netherlands
More
-
May 12, 2009
U.S.
Army funds TNO, and to-BBB
to investigate protecting
soldier’s brains from nerve
agents
More
- May 5, 2009
Viroblock SA Reports a 99%
Boost of Efficacy of Facemasks against H5N1
More
- April 14,
2009
Promising Test for Dendreon's Prostate Cancer
Drug
More
- April 11, 2009
FDA Approves Treatment of Head Lice - Target Health Was THE CRO
More
- April 7, 2009
Dr. Cori Gorman Completes ISS Certification in Corporate Directors
Enterprise 2009 Program
More
- April 7, 2009
Editorial: Enabling High Throughput Drug Development
More
- April 2, 2009
Editorial: Personalized Medicine Can Increase Revenues
More
- March 31, 2009
Selexis launches Biosimilar Cell Line Development Program
More
-
March 31, 2009
Positive Results of Preclinical Studies in
Antiviral Nasal Spray
More
-
March 24, 2009
Editorial: Cell Therapy
Market
Cori Gorman, PhD, MBA
Read Article
|
|
